Details

Autor(en) / Beteiligte

• Ferreri, Christopher J.
• Hildebrandt, Michelle A. T.
• Hashmi, Hamza
• Shune, Leyla O.
• McGuirk, Joseph P.
• Sborov, Douglas W.
• Wagner, Charlotte B.
• Kocoglu, M. Hakan
• Rapoport, Aaron
• Atrash, Shebli
• Voorhees, Peter M.
• Khouri, Jack
• Dima, Danai
• Afrough, Aimaz
• Kaur, Gurbakhash
• Anderson, Larry D.
• Simmons, Gary
• Davis, James A.
• Kalariya, Nilesh
• Peres, Lauren C.
• Lin, Yi
• Janakiram, Murali
• Nadeem, Omar
• Alsina, Melissa
• Locke, Frederick L.
• Sidana, Surbhi
• Hansen, Doris K.
• Patel, Krina K.
• Castaneda Puglianini, Omar Alexis

Titel

Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy

Ist Teil von

• Blood cancer journal (New York), 2023-08, Vol.13 (1), p.117-9, Article 117

Ort / Verlag

London: Nature Publishing Group UK

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• Most patients with multiple myeloma experience disease relapse after treatment with a B-cell maturation antigen-targeted therapy (BCMA-TT), and data describing outcomes for patients treated with sequential BCMA-TT are limited. We analyzed clinical outcomes for patients infused with standard-of-care idecabtagene vicleucel, an anti-BCMA chimeric antigen receptor (CAR) T-cell therapy, at 11 US medical centers. A total of 50 patients with prior BCMA-TT exposure (38 antibody-drug conjugate, 7 bispecific, 5 CAR T) and 153 patients with no prior BCMA-TT were infused with ide-cel, with a median follow-up duration of 4.5 and 6.0 months, respectively. Safety outcomes between cohorts were comparable. The prior BCMA-TT cohort had a lower overall response rate (74% versus 88%; p  = 0.021), median duration of response (7.4 versus 9.6 months; p  = 0.03), and median progression-free survival (3.2 months versus 9.0 months; p  = 0.0002) compared to the cohort without prior BCMA-TT. All five patients who received a prior anti-BCMA CAR T responded to ide-cel, and survival outcomes were best for this subgroup. In conclusion, treatment with ide-cel yielded meaningful clinical responses in real-world patients exposed to a prior BCMA-TT, though response rates and durability were suboptimal compared to those not treated with a prior BCMA-TT.